Table 2.
Standardized Incidence Risk (SIR) according to demographics and treatment in DLBCL survivors.
| Factor | SIR (95%CI) | p value |
|---|---|---|
| Overall SIR | 1.1(0.8–1.5) | |
| Gender | ||
| F | 1.00 (0.57–1.62) | 0.618 |
| M | 2.72 (1.76–4.02) | |
| IPI | ||
| 0–1 | 1.13 (0.69–1.75) | 0.959 |
| 02-mag | 1.15 (0.71–1.76) | |
| Chemotherapy | ||
| PCB-epidoxorubicin | 1.22 (0.78–1.81) | 0.610 |
| PCB-idarubicin | 1.12 (0.45–2.31) | |
| PCB-sequential | 1.24 (0.46–2.70) | |
| CHOP or CHOP like | 0.60 (0.16–1.55) | |
| RT-IF | ||
| No | 1.16 (0.79–1.63) | 0.549 |
| Yes | 0.92 (0.42–1.75) | |
| Cohort Age | ||
| 20–39 | 23.0 (5.76–92.0) | |
| 40–59 | 4.39 (1.92–1.78) |
PCB-epidoxorubicin: ProMECE-CytaBOM: (methylprednisolone, cyclophosphamide, epidoxorubicin -or doxorubicin-, etoposide, cytarabine, bleomycin, vincristine, methotrexate); PCB-idarubicin: ProMICE-CytaBOM (methylprednisolone, cyclophosphamide, idarubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate); PCB-Sequential: sequential ProMECE instead of the classical cycling regimen; CHOP: cyclophosphamide, doxorubicin vincristine, prednisolone. RT-IF: radiotherapy-involved field.